Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis
(2011) Cancer Letters — Vol. 302, n° 1, p. 54-62 (2011)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 469.48 KB
Details
- Authors
- Abstract
- The chemokine granulocyte chemotactic protein (GCP)-2/CXCL6 promotes tumor growth as angiogenesis inducer and neutrophil chemoattractant. The neutralizing capacity and specificity of monoclonal mouse anti-murine (mu)GCP-2/CXCL6 antibodies were evidenced by granulocyte chemotaxis and signaling assays. The half-life of the non-antigenic antibody in the blood circulation was approximately 15. days. The titers remained constant upon weekly injection. Tumor growth and lymphogenic metastases of human melanoma over-expressing muGCP-2 were reduced in mice treated with anti-muGCP-2. Moreover, the drop in muGCP-2 antibody titer correlated with the melanoma tumor size. Taken together, we show that functional blocking of GCP-2 inhibits tumor growth and metastases. © 2010 Elsevier Ireland Ltd.
- Affiliations
Citations
Verbeke, H., Struyf, S., Berghmans, N., Van Coillie, E., Opdenakker, G., Uyttenhove, C., Van Snick, J., & Van Damme, J. (2011). Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis. Cancer Letters, 302(1), 54-62. https://doi.org/10.1016/j.canlet.2010.12.013 (Original work published 2011)